Avalo Therapeutics (AVTX) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Avalo Therapeutics (AVTX) over the last 11 years, with Q2 2025 value amounting to $0.0.
- Avalo Therapeutics' Debt to Equity changed N/A to $0.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $0.0, marking a year-over-year change of. This contributed to the annual value of $0.0 for FY2024, which is N/A changed from last year.
- According to the latest figures from Q2 2025, Avalo Therapeutics' Debt to Equity is $0.0.
- In the past 5 years, Avalo Therapeutics' Debt to Equity registered a high of $1.42 during Q4 2021, and its lowest value of -$8.14 during Q3 2022.
- Over the past 5 years, Avalo Therapeutics' median Debt to Equity value was -$0.62 (recorded in 2022), while the average stood at -$1.59.
- The largest annual percentage gain for Avalo Therapeutics' Debt to Equity in the last 5 years was 18686.05% (2022), contrasted with its biggest fall of 18686.05% (2022).
- Over the past 5 years, Avalo Therapeutics' Debt to Equity (Quarter) stood at $1.42 in 2021, then tumbled by 186.86% to -$1.24 in 2022, then tumbled by 35.22% to -$1.67 in 2023, then soared by 100.16% to $0.0 in 2024, then surged by 30.75% to $0.0 in 2025.
- Its Debt to Equity was $0.0 in Q2 2025, compared to $0.0 in Q1 2025 and $0.0 in Q4 2024.